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Abstract The indications of photodynamic therapy
(PDT) of oral cavity and oropharynx neoplasms are not
well deWned. The main reason is that the success rates are
not well established. The current paper analyzes our institu-
tional experience of early stage oral cavity and oropharynx
neoplasms (Tis-T2) to identify the success rates for each
subgroup according to T stage, primary or non-primary
treatment and subsites. In total, 170 patients with 226
lesions are treated with PDT. From these lesions, 95 are pri-
mary neoplasms, 131 were non-primaries (recurrences and
multiple primaries). The overall response rate is 90.7%
with a complete response rate of 70.8%. Subgroup analysis
identiWed oral tongue, Xoor of mouth sites with more favor-
able outcome. PDT has more favorable results with certain
subsites and with previously untreated lesions. However,
PDT can Wnd its place for treating lesions in previously
treated areas with acceptable results.
Keywords Oral cancer · Oropharynx cancer · 
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Introduction
Photodynamic therapy (PDT) is a relatively new method
for management of head and neck neoplasms. Surgery and
radiotherapy are long accepted as the standard treatment for
head and neck neoplasms with long successful track
records [1, 2]. This standard approach has an established
success rate approaching 95% for early stage neoplasms [3,
4]. The upper aerodigestive tract has important functions,
such as respiration, swallowing and phonation. Standard
treatment of the neoplasms of head and neck region,
although not frequent with superWcial neoplasms, might
compromise one or more of these functions. Especially
with repeated treatments for recurrent and multiple prima-
ries, these problems become more evident [5–8]. New
reconstructive techniques, less invasive surgical modalities
such as laser or robot-assisted endoscopic surgery, more
precise delivery of radiation with techniques, such as inten-
sity-modiWed radiation treatment (IMRT) all aim to
decrease the morbidity rate [9–12].
PDT is searching its role in the era of conservation sur-
gery. The advantage of PDT is local treatment without
long-term systemic eVects. The photosensitizing drug is
activated by the light delivered directly onto the neoplasm
sparing the surrounding normal mucosa. Protection of the
surrounding tissue is further assured by shielding with wet
sponges or special shielding waxes.
An additional advantage of PDT is that it shows its eVect
via cytotoxicity rather than destructive eVects. This means
that when cancer cells are eliminated via apoptosis the
extracellular matrix remains forming a scaVold for the
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Eur Arch Otorhinolaryngolsurrounding mucosal tissue to advance over [13, 14]. Scar
formation is minimal and the native tissue that replaces the
cancer cells maintains its normal functions limiting the
functional loss signiWcantly.
Perhaps, the most important aspect of PDT is its
repeatability. PDT can be applied to the same area with-
out accumulative destructive eVects [15–17]. It also does
not negatively eVect further treatments, such as radiation
or chemotherapy [15], leaving further treatment options
open.
Despite these advantages PDT remains unknown to
many head and neck oncologists [17–20]. Because PDT is
searching its place in the management cascade of head and
neck oncology, we believe it is important to have a basic
knowledge of what degree of success can be expected in
various clinical scenarios. The current paper is aiming to
analyze retrospectively a subgroup of patients with early
stage oral cavity and oropharynx neoplasms to demonstrate
what percentage of success to expect with PDT. This analy-
sis includes neoplasms of diVerent subsites of the oral cav-
ity and oropharynx, primary neoplasms versus recurrences
or multiple primary neoplasms in previously convention-
ally treated Welds.
Materials and methods
The registry of patients (294 patients between 1996 and
2008) treated with PDT was retrospectively screened to
identify patients with early stage (Tis, T1, T2) oral cavity
and oropharynx squamous cell cancers or carcinoma in situ.
One hundred and seventy patients were included in the
analysis.
All patients were subject to pretreatment evaluation
according to the guidelines of our institute.
Pre-treatment work-up
Standard minimum evaluation consisted of biopsy to deter-
mine the histological diagnosis of squamous cell cancer or
carcinoma in situ (Tis); X-ray of the thorax; ultrasound
(US) of the neck and Wne-needle aspiration (FNA) to deter-
mine nodal metastasis situation. Tumor thickness is mea-
sured either by US or magnetic resonance imaging (MRI).
The whole surface of the oral cavity tumors are screened
with an oral US probe to determine the deepest point of
inWltration. Only tumors that have less than or equal to
5 mm depth of invasion were treated with surface PDT.
Oropharyngeal tumors could not be reached by US and,
therefore, evaluated by the less accurate method of MRI. If
the tumors cannot be visualized on the MR images or there
is a surface of contrast uptake, but no evidence of deep
invasion, the patients received PDT. The cut-oV depth of
5 mm is decided to enable treatment of 5 mm margin
deeper than the tumor. The total 10 mm is the average
depth of penetration of the 652 nm light used to activate the
photosensitizer.
The work-up for regional lymphatic status is US of the
neck and FNA of suspected lymph nodes. All patients who
received PDT had N0 stage according to US criteria. The
guidelines of our institute involve no prophylactic neck dis-
sections for T1 and T2 oral cavity tumors if they are candi-
dates for transoral excisions or PDT. The neck node status
is followed by US combined with FNA at 6-month inter-
vals. Patients with suspected lymph nodes receive modiWed
radical neck dissection.
Patients were informed of potential beneWts and risks
of the treatment and instructed about light avoidance
measures and supplied with a light meter to measure
ambient light.mTHPC (temoporWn, Foscan®, Biolytec
Pharma Ltd., Dublin, Ireland) at a dose of 0.15 mg/kg
was injected to a deep vein with slow infusion. Patients
were discharged home after the injection. Illumination
took place 96 h after the mTHPC injection. Light is
delivered by a diode laser at 652 nm. Dose delivered is
20 J/cm2 with a Xuence rate of 100 mW/cm2. Preferred
method is to deliver light with one spot delivered via a
microlens. If one spot illumination is not applicable due
to the shape or location of the neoplasm multiple spots
were used. The lesion plus 5 mm margin of normal
appearing mucosa is illuminated. All patients received
corticosteroids and pain management. Hospital stay
depended on the functional limitations after PDT due to
location and extent of the neoplasm, as well as edema
due to PDT.
Tumor response is analyzed according to the World
Health Organization (WHO) criteria [20]:
Complete response (CR): the disappearance of all
known disease
Partial response (PR): 50% or more decrease in the
dimensions of the tumor
No response (NR): less than 50% decrease or less than
25% increase in tumor dimensions
Progressive disease (PD): 25% or more increase in the
size of one or more measurable lesions or the appear-
ance of new lesions
All responses have to be conWrmed by two observations not
<4 weeks apart. Overall response (OR) is the sum of com-
plete and partial responders.
Follow-up
There is a follow-up schedule of 1, 2, 4, 8, 16, 24, 36,
52 weeks after PDT, followed by routine controls every
4 months for a total of 5 years.123
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Patients
Of the 170 patients evaluated, 80 were female and 90 were
male. The average age at treatment was 60.5 years. A total
of 226 neoplasms was treated with PDT, 35 patients are
treated for 2 or more neoplasms. Of the evaluated neo-
plasms, 95 were primary neoplasms, 131 were non-primary
neoplasms consisting of 65 recurrences, 46 s, 9 third and 3
fourth primary neoplasms and of 8 residual neoplasms after
initial treatment. Previous treatments within the non-pri-
mary neoplasm group (n = 131) include: radiotherapy
48.1%, chemoradiation 22.7%, surgery 75.6% and previous
PDT 30.6%.
Tumor response
The OR rate for all neoplasms is 90.7% (95% CI 86.2–
94.2%) with a CR rate of 70.8% (95% CI 64.4–76.6%). In
Table 1, the responses are listed per site, per stage and
primary or non-primary. The median local disease-free
interval for all of the CR cases is 102.0 months (95% CI
89.6–114.3 months). 2- and 5-year local disease-free survival
rates are 74 and 61%, respectively.
Analysis per T classiWcation
Tis lesions have an OR rate of 94.5% (95% CI 86.6–98.5%),
with a CR rate of 79.5% (95% CI 68.4–88.0%); T1 neo-
plasms have an OR rate of 90.9% (95% CI 84.3–95.4%)
with a CR rate of 68.6% (95% CI 59.5–76.7%); and
for the T2 neoplasms, the OR rate is 81.3% (95% CI
63.6–92.8%) with a CR of 59.4% (95% CI 40.7–76.3%).
The variations in tumor response between the stages are
only statistically signiWcant for Tis versus T2 stage tumors
(P < 0.05). The mean local disease-free interval is 65.7 months
(95% CI 49.3–82.2 months) for the Tis group, 109.1 months
(95% CI 93.1–125.0 months) for T1 and 113.4 months (95%
CI 81.9–144.9 months) for T2 (Fig. 1). The mean sur-
vival time is 92.2 months (95% CI 79.3–105.0 months)
for dys/CIS, 98.4 months (95% CI 84.6–112.2 months) for
T1 and 78.7 months (95% CI 54.2–103.2 months) for T2
tumors.
Sub-site analysis
In Table 1, an overview of all treated sites is shown. The
CR rate is highest for the oral tongue site [94.4% (95% CI
81.3–99.3%)], the Xoor of mouth [76.9% (95% CI 64.8–
86.5%)] and the soft palate [75.9% (95% CI 56.5–89.7%)]
and lowest for the nasal cavity [37.5% (95% CI 0.9–75.5%)],
the alveolar process [42.1% (95% CI 20.3–66.5%)] and the
buccal mucosa [57.7% (95% CI 36.9–76.7%)]. Oral tongue
has signiWcantly better response rate than the rest of the
group (P < 0.05) and alveolar process has signiWcantly
lower response rate than the rest of the group (P < 0.05).
Primary neoplasms versus non-primary neoplasms
Primary neoplasms have an OR rate of 96.8% (95% CI
91.1–99.3%) with a CR rate of 77.9% (95% CI 68.2–
85.8%). For the non-primary neoplasms, the OR rate is
86.2% (95% CI 79.2–91.7%) and the CR rate is 65.6%
(95% CI 56.9–73.7%).
Neoplasms located in an irradiated Weld (n = 64) have a
CR rate of 57.8% (95% CI 44.8–70.1%); neoplasms located
in an area that was treated before with surgery (n = 99)
have a CR rate of 62.6% (95% CI 52.3–72.2%). There is no
statistical diVerence.
The mean local disease-free interval for the primary neo-
plasms with a CR is 117.8 months (95% CI 102.1–
133.6 months). For the non-primary neoplasms with a CR,
the interval is 84.9 months (95% CI 67.2–102.7 months). 1,
2 and 5-year survival of patients with primary neoplasms
are 90, 85 and 74%, respectively. For non-primary neo-
plasms disease-free survival at 1, 2 and 5 years are 81, 64
and 48%, respectively (Fig. 2). The diVerence in local dis-
ease-free survival for primary neoplasms versus non-pri-
mary neoplasms is statistically signiWcant (P < 0.001).
The overall mean survival time for the primary neo-
plasms was 120.4 months (95% CI 106.4–134.4 months)
and for the non-primary neoplasms, this was 82.1 months
(95% CI 67.7–96.5 months) (Fig. 3). The diVerence in sur-
vival time for primary neoplasms versus non-primary neo-
plasms is statistically signiWcant with P < 0.05.
Fig. 1 Local disease-free interval per T stage of neoplasms123
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OR overall response, CR complete response, OR/n number of overall response/total number of patients treated in this subgroup, CR/n number of
complete responders/total number of patients treated in this subgroup
SITE Stage
Dysplasia T1 T2 All stages
OR CR OR CR OR CR OR CR
OR/n % CR/n % OR/n % CR/n % OR/n % CR/n % OR/n % CR/n %
Floor of mouth n = 65
Total 24/25 96.0 22/25 88.0 29/30 96.7 20/30 66.7 9/10 90.0 8/9 80.0 62/65 95.4 50/65 76.9
Primary 7/7 100 6/7 85.7 20/20 100 13/20 65.0 6/6 100 5/6 83.3 33/33 100 24/33 72.7
Non-primary 17/18 94.5 16/18 88.9 9/10 90.0 7/10 70.0 3/4 75.0 ¾ 75.0 29/32 90.6 26/32 81.3
Oral tongue n = 36
Total 12/12 100 10/12 83.3 24/24 100 24/24 100 – – – – 36/36 100 34/36 94.4
Primary 5/5 100 4/5 80.0 17/17 100 17/17 100 – – – – 22/22 100 21/22 95.5
Non-primary 7/7 100 6/7 85.7 7/7 100 7/7 100 – – – – 14/14 100 13/14 92.9
Soft palate n = 29
Total 8/8 100 8/8 100 14/15 93.3 10/15 66.7 4/6 66.7 4/6 66.7 26/29 89.7 22/29 75.9
Primary 2/2 100 2/2 100 7/7 100 4/7 57.1 2/3 66.7 2/3 66.7 11/12 91.7 8/12 66.7
Non-primary 6/6 100 6/6 100 7/8 87.5 6/8 75.0 2/3 66.7 2/3 66.7 15/17 88.2 14/17 82.4
Buccal mucosa n = 26
Total 4/5 80.0 3/5 60.0 13/15 86.7 10/15 66.7 6/6 100 2/6 33.3 23/26 88.5 15/26 57.7
Primary – – – – 7/8 87.5 5/8 62.5 3/3 /100 0/3 0 10/11 90.9 5/11 45.5
Non-primary 4/5 80 3/5 60.0 6/7 85.7 5/7 71.4 3/3 100 2/3 66.7 13/15 86.7 10/15 66.7
Oropharynx n = 26
Total 5/7 71.4 4/7 57.1 11/13 84.6 9/13 69.2 6/6 100 4/6 66.7 22/26 84.6 17/26 65.4
Primary 3/3 100 3/3 100 4/4 100 4/4 100 – – – – 7/7 100 7/7 100
Non-primary 2/4 50.0 1/4 25.0 7/9 77.8 5/9 55.6 6/6 100 4/6 66.7 1,519 78.9 10/19 52.6
Alveolar process n = 19
Total 10/10 100 6/10 60.0 4/7 57.1 2/7 28.6 0/2 0 – – 14/19 73.7 8/19 42.1
Primary 1/1 100 1/1 100 1/1 100 1/1 100 0/1 0 – – 2/3 66.7 2/3 66.7
Non-primary 9/9 100 5/9 55.6 3/6 50.0 1/6 16.7 0/1 0 – – 12/16 75.0 6/16 37.5
Retromolar trigon n = 9
Total 3/3 100 3/3 100 5/5 100 2/5 10.0 1/1 100 1/1 100 9/9 100 6/9 66.7
Primary 2/2 100 2/2 100 2/2 100 2/2 100 1/1 100 1/1 100 5/5 100 5/5 100
Non-primary 1/1 100 1/1 100 3/3 100 0/3 0 – – – – 4/4 100 1/4 25.0
Hard palate n = 8
Total 3/3 100 2/3 66.7 5/5 100 3/5 60.0 – – – – 8/8 100 5/8 62.5
Primary 1/1 100 1/1 100 1/1 100 1/1 100 – – – – 2/2 100 2/2 100
Non-primary 0/2 0 0/2 0 4/4 100 2/4 50.0 – – – – 6/6 100 3/6 50.0
Nasal cavity n = 8
Total – – – – 5/7 71.4 3/7 42.9 0/1 0 – – 5/8 62.5 3/8 37.5
Primary – – – – – – – – – – – – – – – –
Non-primary – – – – 5/7 71.4 3/7 42.9 0/1 0 – – 5/8 62.5 3/8 37.5
Subtotal
Primary 21/21 100 19/21 90.5 59/60 98.3 47/60 78.3 12/14 85.7 8/14 57.1 92/95 96.8 74/95 77.9
Non-primary 48/52 92.3 39/52 75.0 51/61 83.6 36/61 59.0 14/18 77.8 11/18 61.1 113/131 86.3 86/131 65.6
Total 69/73 94.5 58/73 79.5 110/121 90.9 83/121 68.6 26/32 81.3 19/32 59.4 205/226 90.7 160/226 70.8123
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A total of 42 patients (24.7%) had neck metastasis diagnosed
by US and FNA and subsequently treated with neck dissection.
Eighteen of these patients (10.5%) had a neck metastasis com-
bined with a second primary neoplasm or local recurrence. The
staging of the neck after neck dissection was N1 in 26 patients,
N2b in 14 patients, and N2c in 2 patients. There was no N3 or
inoperable neck metastasis detected in this patient series.
Adverse events
Three patients had second degree burn wounds as a result
of failure to comply by light protection guidelines. All of
the burn wounds healed with conservative measurements.
Nine patients had permanent discoloration at the injection
site of mTHPC. Five patients had scar formation in the buc-
cal mucosa leading to mild/moderate trismus. These
patients were managed with conservative measures involv-
ing stretching exercises. Twelve patients had to receive
temporary nasogastric sonda feeding for an average time of
5 days because of inability to swallow. The healing process
after PDT takes 2–5 weeks and the wound heals with mini-
mum scarring after this period. There were no systemic or
serious adverse events.
Discussion
Photodynamic therapy has been used in head and neck
oncology for some time with reported success [17–19, 21–
31]. Unfortunately, there are no studies comparing PDT
with standard treatment methods, such as surgical resection
and radiation therapy. Up to date, all data are over develop-
ing the technique of PDT and not actually comparing it
with other methods. The overall clinical response rate after
PDT as determined by the present analysis is below the
reported success rates of surgery or radiation treatment
[1–4]. The real reason is very diYcult to determine. The
patient groups are not comparable and furthermore addi-
tional treatments, such as re-excision for positive resection
margins and postoperative radiation is often included in the
disease-free survival analysis. The current analysis is focus-
ing on Wnding favorable conditions for PDT and, therefore,
excluding additional treatments, such as surgical resections
from disease-free survival analysis (these patients are com-
puted as failures). The ideal setup for such a comparison
would be randomised study comparing surgical resection
with PDT. However, for this purpose favorable situations,
where PDT can be preferred over surgery, have to be
identiWed.
The PDT literature fails to identify these favoured areas
because of the small numbers of treated patients and the
heterogeneity of treated groups making it impossible to
give a clear answer to the question of what to treat and
maybe more importantly what not to treat. These are all
preliminary studies that were done to establish treatment
protocols for PDT and subsequently treat patients to reach
larger series. The results of such larger series are recently
becoming available to us.
The longest experience is with photofrin-mediated PDT
with the largest series published by Biel with 276 patients
[28]. This series include laryngeal and oral cavity neo-
plasms with T1-3 N0 cancers. The CR rates are impressive
with 91% for laryngeal neoplasms and 94% for oral cavity
tumors. However, there is no subgroup analysis to show if
certain subgroups of neoplasms react better.
Fig. 2 Local disease-free interval, comparing primary neoplasms ver-
sus non-primary neoplasms
Fig. 3 Overall survival, comparing primary neoplasms versus non-
primary neoplasms123
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which is activated with 652 nm light enabling deeper tissue
penetration and providing treatment of deeper neoplasms
[32]. A prospective multinational multi-institutional study
with mTHPC-PDT was carried out with the participation of
our institute [29]. The aimed group was patients with small
neoplasms of the oral cavity with <25 mm of diameter and
<5 mm depth of invasion. This group of well selected oral
cavity tumors showed CR to mTHPC-PDT at a rate of 85%
which is surprisingly lower than photofrin PDT [28].
The 5 mm cut-oV limit is arbitrary. The international
multicentre study carried out by D’Cruz et al. applied PDT
to tumors deeper than 10 mm depth of invasion [30]. Treat-
ment of deeper tumors (up to 50 mm) was justiWed by the
aim of the study, which was to provide palliation to incura-
ble head and neck cancers by conventional methods. This
great range of thickness enabled the authors to compare
tumors with <10 mm depth to tumors with >10 mm depth.
Among completely illuminated lesions with <10 mm depth
had a much better response than deeper tumors, with CR of
60 versus 26% and OR of 75 versus 40%. It is a pity that
they did not choose 5 mm depth as their comparison param-
eter, but we still get the idea that depth of the lesion is very
important.
The choice method we use to determine the depth of the
tumor is ultrasound. Endoscopic US is being used to stage
several digestive system cancers, such as anal cancers with
proven accuracy [33]. Shintani et al. [34] showed that intra-
oral US measurements of depth of tumor correlate well
with histologic specimens. The whole surface of the tumor
should be screened with US not to miss any spot deeper
than 5 mm. The inaccuracy of the US (if there is any) is
compensated by PDT reaching 10 mm depth. The real
problem is with oropharyngeal cancers, where the US probe
cannot reach or cannot scan the entire surface. MRI can be
used to determine depth. If the tumor cannot be seen on MR
images or appear just as a contrast uptake, although there is
no evidence to support it and it can be assumed that the
tumor is <5 mm deep. This method is by no means accurate
and has to be replaced by another method. Introduction of
newer methods, such as optical coherence tomography
(OCT) might help in the future.
Location of the neoplasm
Oral cavity and oropharynx are not homogenous structures
that have constant tissue characteristics. The tissue compo-
sition of the alveolar process is clearly diVerent than that of
the tongue or soft palate. Furthermore, some areas in the
oral cavity and pharynx are Xat while others have a com-
plex geography. Multiple spots might have to be used to
illuminate all the extensions of the neoplasm, theoretically
making the chance of geographic miss greater.
It is, therefore, important to designate the favorable sub-
sites of the oral cavity and oropharynx. The only sub-site
that reacts signiWcantly better is oral tongue. The reason is
probably the relative homogeneity of the tissue with the
absence of nearby bony structures, as well as the relative
ease of delivering the light in a homogeneous manner on
the Xat surface.
Floor of mouth and soft palate have a more complex
anatomy than the oral tongue with proximal bony structures
(i.e. mandible and hard palate) probably causing lower CR
rates. Buccal mucosa has a relatively Xat surface providing
ease of illumination with a rather homogenous structure
with no apparent reason for a poorer outcome than the oral
tongue. Although a statistic comparison is not carried out,
buccal mucosa is also observed to have more scar tissue
causing mild trismus (5/23 patients).
As can be expected, the neoplasms of the alveolar pro-
cess have less CR rate than the overall mean. Alveolar pro-
cess has a more complex anatomy with underlying
mandible and has three surfaces making homogenous illu-
mination harder to achieve. However, it can be argued that
the OR rate of 73.7% helps in reducing the size of the neo-
plasm and enable a smaller excision subsequently.
The study by Hopper et al. [29] is the only publication
reporting success rates for subsites, with CR rates of 89%
for Xoor of mouth, 83% for lip, 93% for anterior tongue and
83% for buccal mucosa. There are publications that report
failures in certain sites, but the numbers are very low to
draw any conclusions [27].
The numbers of retromolar trigon, hard palate and nasal
cavity neoplasms treated with PDT are not enough to do a
statistical analysis (9, 8 and 8 patients, respectively). How-
ever, the CR rates of the retromolar triangle (66.7%) and
hard palate (62.5%) are near the overall mean (70.8%).
The tumors of the oral tongue, which has the best results
to PDT, are also usually easily resectable with minimum
morbidity making PDT an unlikely candidate for initial ther-
apy. Sites that would have functional problems after surgical
resection, such as alveolar process and soft palate, although
have lower response rates to PDT might be treated with PDT
as initial treatment to avoid the functional problems, reserving
surgery and/or radiation treatment for failures.
T stage
It can be an expected result because as the neoplasm area
gets larger delivering light evenly gets harder and the risk
for geographic miss gets greater. In our series, we do not
observe such a diVerence. Although T1 tumors have a bet-
ter CR rate than T2 tumors this is not statistically diVerent
(Table 1). Therefore, we can say that the size of the tumor
does not make a diVerence as long as all of the tumor can be
fully illuminated and the depth of invasion is <5 mm.123
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tumors with 79.5%. Tis recur much earlier than T1 and T2
tumors (mean disease-free interval of 65.7 months for dys-
plasia versus 109.1 months for T1 and 113.4 months for T2
tumors) (Fig. 1). It is well known that patients with Tis of
the upper aerodigestive tract are prone to develop new leu-
koplakia a number of times [35]. It should be kept in mind
that PDT can be repeated a number of times with minimal
morbidity to treat leukoplakia as they recur. The success of
repeated treatments as lesions recur becomes evident by the
similar survival rates of patients with Tis and T1 neo-
plasms. The diVerence in disease-free interval is made up
for either by successful re-treatments or the relatively less
lethal nature of Tis.
Recurrences and multiple primary neoplasms
Recurrences and multiple primary neoplasms pose a chal-
lenge to the head and neck oncologist. Most of these lesions
occur in the previously irradiated or operated Welds [36,
37]. The study by D’Cruz et al. focused on such patients
who had refractory neoplasms of the head and neck area
that were unsuccessfully treated or unsuitable for conven-
tional treatments [30]. They report 38% OR and 16% CR. It
should be noted that this study was a multicentre, multina-
tional study with vague inclusion criteria, resulting in treat-
ment of neoplasms that may not be suitable for surface
PDT. When the lesions that were not fully illuminated and
deeper than 10 mm were excluded they report an OR rate of
54% with 30% CR rate.
In our series, a total of 131 recurrent, second, or multiple
primary neoplasms were treated with PDT. Even though
non-primary neoplasms respond less favorably to PDT than
primary neoplasms (65.9 vs. 77.9% CR, respectively,
P < 0.05), 65.9% CR is a considerable success if we take
into account that the treated area received radiation in
48.1%, chemoradiation in 22.7% and previous surgery in
75.6% of the patients. Furthermore, there is an 86.3% OR
which means that an additional group of lesions decrease in
size which makes subsequent surgical resection smaller.
The diVerence with the study by D’Cruz et al. can be
accounted to the more conservative selection criteria by our
group.
Management of neck nodes
Elective treatment of N0 neck in case of early oral cavity
cancers is a point of debate. Studies comparing elective
neck dissection with wait and see policy show no diVerence
in overall survival [38]. In experienced hands, US of the
neck combined with FNA can reach a sensitivity of 73%
and a speciWcity of 100% [39]. We adopted the wait and see
policy for patients staged as N0 by US of the neck. Neck
recurrences can be detected by regular US and FNA con-
trols and the patients can receive subsequent neck dissec-
tions. This approach resulted in 24.7% patients receiving
neck dissections. All of these patients had resectable neck
nodes which were adequately removed after neck dissec-
tions. The number is quiet high if you take into consider-
ation that the tumors in question are thinner than 5 mm.
This phenomenon can be explained with the association of
the neck recurrence with second primary or recurrent
tumors in almost half of the cases. It can be speculated that
only 13% of the patients had neck recurrences that are asso-
ciated with the tumor treated by PDT. Depending on the
preference and policies of the center, elective neck dissec-
tion can be combined with PDT. The neck dissection has to
be done either before PDT or 2–3 weeks after PDT. There
is no evidence to prefer one timing over the other.
Conclusion
Our institutional experience supports the value of temo-
porWn-PDT in carefully selected patients. The success rate
of PDT is independent of T stage as long as the depth of
invasion does not exceed 5 mm. Although tongue tumors
respond best to PDT, areas that would have functional
problems after resection such as palatum molle, alveolar
process, retromolar trigon can be Wrst treated with PDT to
avoid morbidity and reserving surgery and/or radiation for
failures/recurrences. DiYcult to treat lesions such as recur-
rent neoplasms and multiple primary neoplasms located in
previously irradiated or operated Welds have a very accept-
able CR rate with minimum morbidity, provided that they
are carefully selected for eligibility.
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